当前位置: 首页 >> 检索结果
281. Dynamics of the gut microbiome in FAP patients undergoing intensive endoscopic reduction of polyp burden.
作者: Sayaka Mizutani.;Ayako Tamaki.;Satoshi Shiba.;Felix Salim.;Masayoshi Yamada.;Hiroyuki Takamaru.;Takeshi Nakajima.;Naohisa Yoshida.;Shoko Ikuta.;Tatsuo Yachida.;Tatsuhiro Shibata.;Tomoyoshi Soga.;Yutaka Saito.;Shinji Fukuda.;Hideki Ishikawa.;Takuji Yamada.;Shinichi Yachida.
来源: Gut. 2025年74卷2期335-338页 283. Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease.
作者: Xiao-Dong Zhou.;Seung Up Kim.;Terry Cheuk-Fung Yip.;Salvatore Petta.;Atsushi Nakajima.;Emmanuel Tsochatzis.;Jérôme Boursier.;Elisabetta Bugianesi.;Hannes Hagström.;Wah Kheong Chan.;Manuel Romero-Gomez.;José Luis Calleja.;Victor de Lédinghen.;Laurent Castéra.;Arun J Sanyal.;George Boon-Bee Goh.;Philip N Newsome.;Jiangao Fan.;Michelle Lai.;Céline Fournier-Poizat.;Hye Won Lee.;Grace Lai-Hung Wong.;Angelo Armandi.;Ying Shang.;Grazia Pennisi.;Elba Llop.;Masato Yoneda.;Marc de Saint-Loup.;Clemence M Canivet.;Carmen Lara-Romero.;Rocio Gallego-Duràn.;Amon Asgharpour.;Kevin Kim-Jun Teh.;Sara Mahgoub.;Mandy Sau-Wai Chan.;Huapeng Lin.;Wen-Yue Liu.;Giovanni Targher.;Christopher D Byrne.;Vincent Wai-Sun Wong.;Ming-Hua Zheng.; .
来源: Gut. 2024年73卷11期1883-1892页
Statins have multiple benefits in patients with metabolic-associated steatotic liver disease (MASLD).
285. Association of breast milk-derived arachidonic acid-induced infant gut dysbiosis with the onset of atopic dermatitis.
作者: Suhua Jiang.;Mengyun Cai.;Dingru Li.;Xiangping Chen.;Xiaoqian Chen.;Qitao Huang.;Caimei Zhong.;Xiufeng Zheng.;Dan Zhou.;Zhiyan Chen.;Lin Zhang.;Jessica Yl Ching.;Ailing Chen.;Shaoxia Lu.;Lifang Zhang.;Ling Hu.;Yan Liao.;Ying Li.;Zhihua He.;Jingjing Wu.;Huiyi Huo.;Yongqi Liang.;Wanwen Li.;Yanli Zou.;Wei Luo.;Siew C Ng.;Francis Kl Chan.;Xia Chen.;Yuhua Deng.
来源: Gut. 2024年74卷1期45-57页
The specific breast milk-derived metabolites that mediate host-microbiota interactions and contribute to the onset of atopic dermatitis (AD) remain unknown and require further investigation.
286. Combination of carvedilol with variceal band ligation in prevention of first variceal bleed in Child-Turcotte-Pugh B and C cirrhosis with high-risk oesophageal varices: the 'CAVARLY TRIAL'.
作者: Harsh Vardhan Tevethia.;Apurva Pande.;Rajan Vijayaraghavan.;Guresh Kumar.;Shiv Kumar Sarin.
来源: Gut. 2024年73卷11期1844-1853页
Beta-blockers and endoscopic variceal band ligation (VBL) have been preferred therapies for primary prophylaxis of variceal bleeding. However, the choice of therapy in patients with advanced liver disease with high-risk varices is not clear. A comparison of these therapies alone or in combination to prevent the first variceal bleed in advanced cirrhosis patients was carried out.
288. Impact of prenatal and postnatal maternal IBD status on offspring's risk of IBD: a population-based cohort study.
作者: Linéa Bonfils.;Gry Poulsen.;Manasi Agrawal.;Mette Julsgaard.;Joana Torres.;Tine Jess.;Kristine Højgaard Allin.
来源: Gut. 2025年74卷2期206-213页
In utero exposure to maternal inflammation may impact immune system development and subsequent risk of disease. We investigated whether a maternal diagnosis of IBD before childbirth is linked to a higher risk of IBD in offspring compared with a diagnosis after childbirth. Further, we analysed paternal IBD status for comparison.
289. Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments.
作者: Claudia Campani.;Sandrine Imbeaud.;Gabrielle Couchy.;Marianne Ziol.;Theo Z Hirsch.;Sandra Rebouissou.;Bénédicte Noblet.;Pierre Nahon.;Katia Hormigos.;Sabrina Sidali.;Olivier Seror.;Valerie Taly.;Nathalie Ganne Carrie.;Pierre Laurent-Puig.;Jessica Zucman-Rossi.;Jean-Charles Nault.
来源: Gut. 2024年73卷11期1870-1882页
Circulating tumour DNA (ctDNA) is a promising non-invasive biomarker in cancer. We aim to assess the dynamic of ctDNA in patients with hepatocellular carcinoma (HCC).
291. HBcrAg values may predict virological and immunological responses to pegIFN-α in NUC-suppressed HBeAg-negative chronic hepatitis B.
作者: Andrea Vecchi.;Marzia Rossi.;Camilla Tiezzi.;Paola Fisicaro.;Sara Doselli.;Elena Adelina Gabor.;Amalia Penna.;Ilaria Montali.;Camilla Ceccatelli Berti.;Valentina Reverberi.;Anna Montali.;Simon P Fletcher.;Elisabetta Degasperi.;Dana Sambarino.;Diletta Laccabue.;Floriana Facchetti.;Simona Schivazappa.;Elisabetta Loggi.;Barbara Coco.;Daniela Cavallone.;Elena Rosselli Del Turco.;Marco Massari.;Giuseppe Pedrazzi.;Gabriele Missale.;Gabriella Verucchi.;Pietro Andreone.;Maurizia Rossana Brunetto.;Pietro Lampertico.;Carlo Ferrari.;Carolina Boni.
来源: Gut. 2024年73卷10期1737-1748页
Selected populations of patients with chronic hepatitis B (CHB) may benefit from a combined use of pegylated interferon-alpha (pegIFN-α) and nucleos(t)ides (NUCs). The aim of our study was to assess the immunomodulatory effect of pegIFN-α on T and natural killer (NK) cell responses in NUC-suppressed patients to identify cellular and/or serological parameters to predict better T cell-restoring effect and better control of infection in response to pegIFN-α for a tailored application of IFN-α add-on.
292. Faecal proteomics links neutrophil degranulation with mortality in patients with alcohol-associated hepatitis.
作者: Henriette Kreimeyer.;Carlos G Gonzalez.;Marcos F Fondevila.;Cynthia L Hsu.;Phillipp Hartmann.;Xinlian Zhang.;Peter Stärkel.;Francisco Bosques-Padilla.;Elizabeth C Verna.;Juan G Abraldes.;Robert S Brown.;Victor Vargas.;Jose Altamirano.;Juan Caballería.;Debbie L Shawcross.;Alexandre Louvet.;Michael R Lucey.;Philippe Mathurin.;Guadalupe Garcia-Tsao.;Ramón Bataller.;AlcHepNet Investigators.;David J Gonzalez.;Bernd Schnabl.
来源: Gut. 2024年74卷1期103-115页
Patients with alcohol-associated hepatitis (AH) have a high mortality. Alcohol exacerbates liver damage by inducing gut dysbiosis, bacterial translocation and inflammation, which is characterised by increased numbers of circulating and hepatic neutrophils.
296. Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet?
Despite significant advances in biologic and small molecule treatments and the emergence of combination therapies to treat inflammatory bowel diseases (IBD) a large unmet need remains to control intestinal inflammation. New approaches targeting several pathways simultaneously with a favorable safety profile and agents that trigger anti-inflammatory pathways to drive durable resolution of inflammation are needed. This article discusses novel cellular immunotherapies and immune cell depleting therapies in IBD, including CAR-T cell approaches, Tr1 and T regulatory (Treg) cells and cell depleting antibodies such as rosnilimab. These novel approaches have the potential to overcome current therapeutic limitations in the treatment of IBD.
298. Prevalence of irritable bowel syndrome and functional dyspepsia after acute gastroenteritis: systematic review and meta-analysis.
作者: Serena Porcari.;Maria Rosa Ingrosso.;Marcello Maida.;Leonardo Henry Eusebi.;Christopher Black.;Antonio Gasbarrini.;Giovanni Cammarota.;Alexander Charles Ford.;Gianluca Ianiro.
来源: Gut. 2024年73卷9期1431-1440页
Disorders of gut-brain interaction may arise after acute gastroenteritis. Data on the influence of pathogen type on the risk of postinfection IBS (PI-IBS), as on postinfection functional dyspepsia (PI-FD), are limited. We conducted a systematic review and meta-analysis to determine prevalence of PI-IBS or PI-FD after acute gastroenteritis.
299. Untargeted faecal metabolomics for the discovery of biomarkers and treatment targets for inflammatory bowel diseases.
作者: Arnau Vich Vila.;Jingwan Zhang.;Moting Liu.;Klaas Nico Faber.;Rinse K Weersma.
来源: Gut. 2024年73卷11期1909-1920页
The gut microbiome has been recognised as a key component in the pathogenesis of inflammatory bowel diseases (IBD), and the wide range of metabolites produced by gut bacteria are an important mechanism by which the human microbiome interacts with host immunity or host metabolism. High-throughput metabolomic profiling and novel computational approaches now allow for comprehensive assessment of thousands of metabolites in diverse biomaterials, including faecal samples. Several groups of metabolites, including short-chain fatty acids, tryptophan metabolites and bile acids, have been associated with IBD. In this Recent Advances article, we describe the contribution of metabolomics research to the field of IBD, with a focus on faecal metabolomics. We discuss the latest findings on the significance of these metabolites for IBD prognosis and therapeutic interventions and offer insights into the future directions of metabolomics research.
300. Glutamine metabolic competition drives immunosuppressive reprogramming of intratumour GPR109A+ myeloid cells to promote liver cancer progression.
作者: Yang Yang.;Tianduo Pei.;Chaobao Liu.;Mingtao Cao.;Xiaolin Hu.;Jie Yuan.;Fengqian Chen.;Bao Guo.;Yuemei Hong.;Jibin Liu.;Bin Li.;Xiaoguang Li.;Hui Wang.
来源: Gut. 2025年74卷2期255-269页
The metabolic characteristics of liver cancer drive considerable hurdles to immune cells function and cancer immunotherapy. However, how metabolic reprograming in the tumour microenvironment impairs the antitumour immune response remains unclear.
|